Glaukos Co. (NYSE:GKOS) Director Sells $392,010.00 in Stock

Glaukos Co. (NYSE:GKOS) Director Gilbert H. Kliman sold 3,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,225,345.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Glaukos Stock Performance

GKOS stock opened at $126.28 on Friday. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of -43.85 and a beta of 1.03. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $136.60. The business’s fifty day simple moving average is $124.45 and its two-hundred day simple moving average is $109.86. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). The company had revenue of $95.70 million for the quarter, compared to analysts’ expectations of $88.86 million. Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. Glaukos’s revenue was up 19.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.55) earnings per share. Analysts predict that Glaukos Co. will post -2.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several recent research reports. Morgan Stanley upped their target price on shares of Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Piper Sandler upped their price objective on Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Wells Fargo & Company lifted their target price on Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Needham & Company LLC increased their price target on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, BTIG Research raised their price target on Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $129.82.

Hedge Funds Weigh In On Glaukos

Institutional investors have recently made changes to their positions in the company. National Bank of Canada FI purchased a new stake in Glaukos in the fourth quarter worth about $46,000. Quadrant Capital Group LLC raised its holdings in shares of Glaukos by 54.8% in the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after purchasing an additional 329 shares in the last quarter. Caldwell Sutter Capital Inc. lifted its position in shares of Glaukos by 5,860.0% in the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 1,465 shares during the period. GAMMA Investing LLC boosted its stake in shares of Glaukos by 68.8% during the second quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after purchasing an additional 486 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC purchased a new position in Glaukos during the second quarter valued at approximately $187,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.